A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Healthy Volunteer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Only males
Description
The primary objective of the study is to characterize the biotransformation and excretion of [14C]-CC-90009 following a single intravenous (IV) dose of 0.6 mg [14C]-CC-90009 in healthy male subjects. The secondary objective of the study is to evaluate the safety and tolerability. The total radioacti...
The primary objective of the study is to characterize the biotransformation and excretion of [14C]-CC-90009 following a single intravenous (IV) dose of 0.6 mg [14C]-CC-90009 in healthy male subjects. The secondary objective of the study is to evaluate the safety and tolerability. The total radioactivity of [14C]-CC-90009 will be 2 ?Ci.
Tracking Information
- NCT #
- NCT04297124
- Collaborators
- Not Provided
- Investigators
- Study Director: Kofi Mensah, MD PhD Bristol-Myers Squibb
Get Well Soon